New drug combo targets brain inflammation in ALS – hope for slower decline
Disease control
Not yet recruiting
This study tests whether a combination of two drugs (galunisertib and nerandomilast) can slow the progression of ALS in people who have high levels of a protein called GREM2. The drugs aim to reduce harmful inflammation and scarring in the brain and spinal cord. The trial will in…
Phase: PHASE2, PHASE3 • Sponsor: Gipfel Life Sciences GmbH • Aim: Disease control
Last updated May 26, 2026 12:04 UTC